Register Now
Enduring Materials
Date of release: 11/10/14
Expiration date: 11/9/16
Policy on Faculty and Provider Disclosure:
It is the policy of the Johns Hopkins University School of Medicine that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the course materials.
THE FOLLOWING RELATIONSHIPS HAVE BEEN REPORTED FOR THIS ACTIVITY
PLANNER:
| Name | Relationships |
|---|---|
| Michael P. Boyle, MD, FCCP | Scientific Advisory Board: Gilead Sciences, Inc., Novartis Pharmaceuticals, Savara Pharmaceuticals, Vertex Pharmaceuticals Incorporated Principal Investigator: Vertex Pharmaceuticals Incorporated |
No other planners have indicated that they have any financial interests or relationships with a commercial entity.
SPEAKERS:
| Name | Lecture Title | Relationships |
|---|---|---|
| Harm Tiddens, MD | Approaches to Treating this Patient |
Grant/Research Funding: Gilead Sciences, Inc., Chiesi Farmaceutici Honoraria: Gilead Sciences, Inc. |
| Claire Wainwright, MBBS, MRCP, FRACP, MD | What to do When Reinfection Occurs |
Grant/Research Funding: Novartis Pharmaceuticals, Vertex Pharmaceuticals Incorporated Advisory Board: Vertex Pharmaceuticals Incorporated Honoraria: Vertex Pharmaceuticals Incorporated |
No other faculty members have indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).
OFF-LABEL PRODUCT DISCUSSION
The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products:
| Name | Lecture Title(s) | Product |
|---|---|---|
| Peter J. Mogayzel, Jr, MD, PhD | Q&A | tobramycin inhalation solution, aztreonam inhalation solution, colistin, ciprofloxacin |
| Margaret Rosenfeld, MD, MPH | Why Eradication – A Clinical Perspective; Q&A | tobramycin inhalation solution, aztreonam inhalation solution, colistin, ciprofloxacin |
| Harm Tiddens, MD | Approaches to Treating this Patient; Q&A | tobramycin inhalation solution, aztreonam inhalation solution, colistin, ciprofloxacin |
| Donna Peeler, RN, BSN | Q&A | tobramycin inhalation solution, aztreonam inhalation solution, colistin, ciprofloxacin |
| Claire Wainwright, MBBS, MRCP, FRACP, MD | What to do When Reinfection Occurs; Q&A | tobramycin inhalation solution, aztreonam inhalation solution, colistin, ciprofloxacin |